Sign inJoin waitlistJoin the waitlist

Gurkamal Chatta

Chief, Genitourinary Medicine · University of Chicago Medical Center

Credentials: · · · · · · ·

History

Genitourinary Medicine Division · University of Chicago Medical Center
Present
Genitourinary Medicine Division · ROSWELL PARK CANCER INSTITUTE
Present

Hematology and Medical Oncology
University of Washington School of Medicine
1989–1992
University of Wisconsin School of Medicine and Public Health
1985–1988
Safdarjang Hospital
1981–1982
– MBBS – University College of Medical Sciences, Delhi University, Delhi, India
1977–1981

Research

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
New England Journal of Medicine · 2023 · 445 citations
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II…
Journal of Clinical Oncology · 2007 · 304 citations
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT…
Journal of Clinical Oncology · 2007 · 249 citations

Igor Puzanov
11 papers
Daniel Petrylak
8 papers
Khurshid Guru
8 papers
David Dale
7 papers
David Quinn
7 papers
DG
Dharmesh Gopalakrishnan
6 papers
Jiaoti Huang
6 papers · 4 as a resident
Primo Lara
6 papers
Przemyslaw Twardowski
6 papers
Carl Morrison
5 papers
David Gandara
5 papers
Maha Hussain
5 papers

Grants

Integrating Cancer and Aging
National Cancer Institute · P20
Contact PI · $618.6K · University of Pittsburgh at Pittsburgh
2003–2010
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $7.7K · University of Pittsburgh at Pittsburgh
2004–2006
Immunologic Therapy of Prostate Cancer
National Cancer Institute · R29
Contact PI · $514.5K · University of Pittsburgh at Pittsburgh
1997–2003

Clinical trials

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Principal investigator · Terminated · Phase 1
Roswell Park Cancer Institute
2022–2025
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Principal investigator · Withdrawn · Phase 1, Phase 2
Roswell Park Cancer Institute
2021–2024
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Principal investigator · Active not recruiting · Phase 2
Roswell Park Cancer Institute
2019–2027
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Principal investigator · Completed · Phase 1
Roswell Park Cancer Institute
2019–2023